Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Solid Cancer × pembrolizumab × Clear all

Phase

Status

Terminated 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 65 Melanoma 45 Squamous Cell Carcinoma of Head and Neck 36 Neoplasms 23 Neoplasm Metastasis 23 Colorectal Neoplasms 22 Breast Neoplasms 22 Head and Neck Neoplasms 20 Carcinoma, Renal Cell 18 Triple Negative Breast Neoplasms 17 Stomach Neoplasms 16 Ovarian Neoplasms 16 Carcinoma, Transitional Cell 15 Esophageal Neoplasms 12 Lung Neoplasms 11 Uterine Cervical Neoplasms 10 Parkinson Disease 4, Autosomal Dominant Lewy Body 10 Carcinoma, Hepatocellular 10 Urinary Bladder Neoplasms 9 Pancreatic Neoplasms 9 Small Cell Lung Carcinoma 8 Multiple Myeloma 8 Recurrence 7 Endometrial Neoplasms 7 Carcinoma, Merkel Cell 7 Mesothelioma 6 Lymphoma, Non-Hodgkin 6 Skin Neoplasms 5 Prostatic Neoplasms 5 Mesothelioma, Malignant 5

Interventions

pembrolizumab 1 durvalumab 1 atezolizumab 1 S-Adenosylmethionine 1 Nivolumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03721679 2021-02-01

Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1

Oncovir, Inc.

Phase 1/2 Terminated

Solid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡